Should the first priority in cardiovascular risk management be those with prior cardiovascular disease?

Heart

Volumn 95, Issue 2, 2009, Pages 125-129

  Kerr, A J ^a,b   Broad, J ^a   Wells, S ^a   Riddell, T ^a   Jackson, R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MORBIDITY; PRIORITY JOURNAL; RISK MANAGEMENT;

ADULT; CARDIOVASCULAR DISEASES; EPIDEMIOLOGIC METHODS; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 61449098571     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2007.140905     Document Type: Article

References (17)

1. Jackson R, Lawes CMM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005;365:434-41.
2. Anderson KM, Odell PM, Wilson PW, at al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8.
3. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136.
4. Woodward M, Brindle P, Tunstall-Pedoe H, at al. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007;93:172-6.
5. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Haart J 2003;24:987-1003.
6. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Haart J 2000;139:272-81. (Erratum appears in Am Haart J 2002;143:21.]
7. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prav Rahab 2003;10:S1-10.
8. New Zealand Guidelines Group. The assessment and management of cardiovascular risk. Wellington, New Zealand, 2003. http://www.nzgg.org.nz/ guidelines/0035/CVD-Risk-Full.pdf
9. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-9.
11. Bannink L, Wells S, Broad J, et al. Web-based assessment of cardiovascular disease risk in routine primary care practice in New Zealand: the first 18,000 patients (PREDICT CVD-1). N Z Med J 2006;119: U2313.
12. National Centre for Classification in Health (Sydney NSW). International statistical classification of diseases and related health problems, 10th revision, Australian modification (ICD-10-CM). 4th ed. Sydney: National Centre for Classification in Health, 2004.
13. El-Jack S, Kerr A. Secondary prevention in coronary artery disease patients in South Auckland: moving targets and the current treatment gap. NZ Med J 2003;116:U664.
14. Euroaspire I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. [See comment.] Lancet 2001;357:995-1001.
15. Sinclair G, Kerr A. The Bold Promise Project: a system change in primary care to support cardiovascular risk screening. N Z Med J 2006;119:U2312.
16. Wells S, Broad J, Jackson R. Estimated prevalence of cardiovascular disease and distribution of cardiovascular risk in New Zealanders: data for healthcare planners, funders, and providers. NZ Med J 2006;119:U1935.
17. Marshall RJ. Scaled rectangle diagrams can be used to visualize clinical and epidemiological data. J Clin Epidemiol 2005;58:974- 81.